Search results

Skip to results

Type

Status

Last updated

Showing 1 to 9 of 9 results for bicalutamide

  1. Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [ID6452]

    In development Reference number: GID-TA11557 Expected publication date:  11 September 2025

  2. Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]

    In development Reference number: GID-TA11730 Expected publication date:  05 November 2025

  3. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.

  4. Prostate cancer: diagnosis and management (NG131)

    This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.

  5. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued Reference number: GID-TA10377

  6. Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

    Evidence-based recommendations on abiraterone (Zytiga) for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.

  7. Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)

    Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.

  8. Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

  9. Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.